Colorcon Corporation has released an impressive new direct compression starch excipient, StarTab™. The launch of StarTab marks a new breakthrough in starch direct compression technology. Due to its unique particle size and shape, StarTab exhibits excellent flow and compressibility on high-speed tablet presses; with StarTab, formulation researchers can also simplify complex tablet formulations while reducing time-consuming manufacturing steps.
In addition, StarTab also plays an important role in improving the stability of moisture-sensitive drugs. This new product launch underscores Colorcon's continued global leadership in bringing specialty excipients and film coating systems to market. These professional accessories are characterized by fast, efficient, cost-effective and reliable performance, which greatly improves the convenience of use.
Through the extended release alliance with DowDuPont, Colorcon introduced and expanded functional film coating products.
DuPont Nutrition & Health, a business unit of DowDuPont Specialty Products, has agreed to expand the existing ER Alliance line of products distributed through Colorcon. The extended release technology provided by the Extended Release Alliance and specialty excipients from DowDuPont will expand to include the Aquacoat® series of extended release coating products for pharmaceutical and nutraceutical applications.
The Aquacoat® product line includes Aquacoat® ECD for extended release applications and Aquacoat® CPD for enteric coating applications. These aqueous functional film coating systems can be applied to both pharmaceutical and nutraceutical solid dosage forms and complement Colorcon's existing line of extended release coatings. They enable tunable drug release profiles and are accepted by regulations worldwide.
Aquacoat® is a registered trademark of DuPont and its affiliates
White Paper: Simplifying the Manufacture of Extended-Release Matrix Tablets Using Direct Compression
The preparation of ER matrix tablets by wet granulation is a complex and time-consuming process, and the many steps often lead to manufacturing challenges and batch-to-batch variability. Direct compression hypromellose (HPMC) can provide a unique solution for powder direct processing. Compared with wet granulation, the direct compression process can save 60% of process time and cost, and can achieve equal or better performance in terms of tablet performance and drug release of the matrix formulation.
In this material, we introduced that the use of METHOCEL™ DC2 direct compression hypromellose can avoid the time-consuming and laborious wet granulation process, save the process time and cost of tablet preparation, and due to the simplification of production steps And reduce the complexity of production and reduce regulatory obstacles, so that products can enter the market faster.